CD33 and neoplasm: When we analyzed the in vivo antitumor activity of anti-CD33.CAR genetically modified EBV-CTLs in AML10-bearing mice, we observed that, compared to untreated mice or to mice receiving EBV-CTLs, anti-CD33.CAR-expressing EBV-CTLs reduced tumor progression (tumor inhibition rate 43% versus 12%, P ≤ 0.05, Wilcoxon rank sum test) (Figures 5(a) and 5(b)).